Loading
A phase 3 trial of Lenvatinib in hepatocellular carcinoma, run by CStone Pharmaceuticals, active and no longer recruiting.
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma is a phase 3 interventional study registered as NCT04194775 by CStone Pharmaceuticals, with 534 participants enrolled, started 2019-12-13 and due to reach its primary completion in 2025-06-18. Interventions recorded: Nofazinlimab (CS1003)+Lenvatinib, Nofazinlimab (CS1003) Placebo+Lenvatinib. Conditions listed: Hepatocellular Carcinoma. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
534 enrolled.
95% CI 18.6 to 24.6; Figures from the ClinicalTrials.gov results section (first posted 2026-07-30), not from a publication · 95% CI 14.7 to 21.8
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Survival (OS)primary | Nofazinlimab + Lenvatinib | 353 | 21.6 months | - | - | link |
| Placebo + Lenvatinib | 181 | 18.5 months |
Shares Advanced hepatocellular carcinoma (BCLC C), Lenvatinib, Anti-angiogenic therapy, Hepatocellular carcinoma.
Shares Lenvatinib, Anti-angiogenic therapy, Hepatocellular carcinoma, Small-molecule kinase inhibitors.
Shares Advanced hepatocellular carcinoma (BCLC C), Anti-angiogenic therapy, Hepatocellular carcinoma, Small-molecule kinase inhibitors.
Shares Advanced hepatocellular carcinoma (BCLC C), Anti-angiogenic therapy, Hepatocellular carcinoma, Small-molecule kinase inhibitors.
Shares Advanced hepatocellular carcinoma (BCLC C), Lenvatinib, Anti-angiogenic therapy, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Anti-angiogenic therapy, Hepatocellular carcinoma, Small-molecule kinase inhibitors.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Lenvatinib, Anti-angiogenic therapy, Hepatocellular carcinoma, Small-molecule kinase inhibitors.